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BACKGROUND:Wepreviously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted
in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular
subgroup analysis of treatment outcomes in patients who had specimens available for analysis was undertaken.
METHODS: Epidermal growth factor receptor (EGFR), KRAS, and PIK3CA mutations were evaluated using peptide
nucleic acid–locked nucleic acid polymerase chain reaction clamp reactions. Survival and response rates (RRs) were
analyzed according to the mutational status. Sixty-four patients (48.1%) were available for mutational analysis in the
chemotherapy alone group and 61 (45.1%) in the chemotherapy plus erlotinib group.RESULTS: 1.6% (2/116) harbored
an EGFRmutation (2 patients; exon 20), 9.6% (12/121) harbored a KRASmutation (12 patients; exon 2), and 9.6% (12/
118) harbored a PIK3CA mutation (10 patients, exon 9 and 2 patients, exon 20). The addition of erlotinib to GEMOX in
patients with KRAS wild-type disease (n = 109) resulted in significant improvements in overall response compared
with GEMOX alone (30.2% vs 12.5%, P = .024). In 95 patients with both wild-type KRAS and PIK3CA, there was
evidence of a benefit associatedwith the addition of erlotinib toGEMOXwith respect to RR as comparedwithGEMOX
alone (P= .04).CONCLUSION: This study demonstrates that KRASmutational statusmight be considered a predictive
biomarker for the response to erlotinib in BTCs. Additionally, the mutation status of PIK3CA may be a determinant for
adding erlotinib to chemotherapy in KRAS wild-type BTCs.
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In South Korea, biliary tract cancers (BTCs), including cholangio-
carcinoma and gallbladder cancer (GBC), are not uncommon [1].
Due to the non-specific symptoms associated with BTCs, more than
75% of cases are unresectable because of the advanced stage of disease
at diagnosis. Moreover, even after a complete resection, many patients
experience a recurrence of disease. Patients with advanced or recurrent
BTCs can be considered for palliative chemotherapy [2,3].
Combination chemotherapy with gemcitabine and a platinum-based
agent is regarded as a standard first-line chemotherapy for advanced
BTC, based on the results of previous randomized phase II and III
trials (ABC01 and 02) [4,5]. Nevertheless, prognosis is still poor andoverall survival (OS) is less than 12 months in patients with advanced or
recurrent BTCs [5].
Figure 1. Consort.
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tion with chemotherapy, have emerged as the standard treatment for a
variety of cancer types [6,7]. These therapies have been applied to
treatment of BTCs. Erlotinib is an orally active tyrosine kinase
inhibitor of epidermal growth factor receptor (EGFR), which has
been associated with improved outcomes in various cancers [8].
Erlotinib, alone or in combination, has shown promising results inTable 1. Characteristics of 125 Advanced BTC Patients Treated with GEMOX with or
without Erlotinib
ITT Population Mutation Analysis Population
GEMOX
(n = 133)
GEMOX Plus
Erlotinib (n = 135)
GEMOX
(n = 64)
GEMOX Plus
Erlotinib (n = 61)
Age, years
Median 61 (55-68) 59 (54-66) 61 (45-77) 58 (39-77)
Sex
Male 79 (59%) 91 (67%) 42 (65.6%) 39 (63.9%)
Female 54 (41%) 44 (33%) 22 (34.4%) 22 (36.1%)
Primary site
Cholangiocarcinoma
(intra-hepatic and
extra-hepatic)
84 (63%) 96 (71%) 43 (67.2%) 44 (72.1%)
Gallbladder 47 (35%) 35 (26%) 20 (31.3%) 14 (23.0%)
AoV 2 (2%) 4 (3%) 1 (1.6%) 3 (4.9%)
Differentiation
Well 6 (5%) 11 (8%) 3 (4.7%) 7 (11.5%)
Moderate 92 (69%) 91 (67%) 36 (56.3%) 28 (45.9%)
Poorly or unknown 35 (26%) 33 (24%) 25 (39.1%) 26 (42.6%)
EOCG performance status
0 20 (15%) 26 (19%) 5 (7.8%) 7 (11.5%)
1 100 (75%) 104 (77%) 56 (87.5%) 54 (88.5%)
2 13 (10%) 5 (4%) 1 (1.6%) -
Disease status
Recurrent 23 (17%) 31 (23%) 16 (25.0%) 22 (36.1%)
Primarily metastatic 110 (83%) 104 (77%) 48 (75.0%) 39 (63.9%)
Liver-only metastasis
Yes 46 (35%) 42 (31%) 13 (20.3%) 10 (16.4%)
No 87 (65%) 93 (69%) 51 (79.7%) 51 (83.6%)
Number of metastatic sites
1 82 (62%) 84 (62%) 52 (81.3%) 52 (85.2%)
2≤ 51 (38%) 51 (38%) 12 (18.8%) 9 (14.7%)phase II trials in patients with advanced BTC, with response rates
(RRs) of 8% to 12%, median OS of 7.5 to 9.9 months, and median
time to progression of 2.6 to 4.4 months [9,10]. In our phase III trial
(NCT01149122) of gemcitabine and oxaliplatin (GEMOX) with or
without erlotinib, the median progression-free survival (PFS) was 4.2
months in the GEMOX group and 5.8 months in the GEMOX plus
erlotinib group [11]. Results of this phase III trial suggested that the
addition of erlotinib to GEMOXmight be a new treatment option for
patients with cholangiocarcinoma, although no significant difference
in PFS was noted between the groups.
BTCs have a spectrum of mutations in EGFR and its downstream
signaling pathways, which include EGFR, KRAS, and PIK3CA [12–
15]. The EGFR signaling pathway has been extensively explored for
several years as a therapeutic target for cancer therapy. Dysregulation
of EGFR signaling has been shown to stimulate cell proliferation,
angiogenesis, and metastatic spread while inhibiting apoptosis. It is
well known that oncogenic activation of EGFR and its downstream
pathways, including KRAS, BRAF, PTEN, PIK3CA, and AKT, is
correlated with responsiveness to anti-EGFR therapies [16,17]. Given
the evidence that KRAS mutations are associated with less efficient
EGFR-directed targeted therapy in various cancer types [18,19], we
evaluated KRAS mutation status in 60 of 268 patients who were
enrolled in our previous phase III trial [11]. However, the predictiveTable 2. Mutational Spectrum of EGFR, KRAS, and PIK3CA
Gene Gallbladder, n = 34, (%) Cholangiocarcinoma, n = 87, (%) AoV, n = 4, (%)
EGFR 0 (0.0%) 2 (2.3%) 0 (0.0%)
T790M 0 (0.0%) 2 (2.3%) 0 (0.0%)
KRAS 4 (11.7%) 7 (8.0%) 1 (25%)
Codon 12 4 (11.7%) 6 (6.9%) 1 (25%)
Codon 13 0 (0.0%) 1 (1.1%) 0 (0.0%)
PIK3CA 0 (0.0%) 12 (13.8%) 0 (0.0%)
E542 0 (0.0%) 3 (3.5%) 0 (0.0%)
E545 0 (0.0%) 7 (8.0%) 0 (0.0%)
H1047 0 (0.0%) 2 (2.3%) 0 (0.0%)
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42 Molecular Subgroup Analysis in Advanced BTC Kim et al. Translational Oncology Vol. 8, No. 1, 2015value of KRAS mutation for response to erlotinib was limited by the
small number of tissues we analyzed.
Herein, to clarify the roles of EGFR, KRAS, and PIK3CA as
predictive biomarkers in patients with advanced BTC who received
erlotinib, we investigated the mutational status of tumors from
archival specimens in an expanded subset of patients enrolled on
our study.
Patients and Methods
Patients and Samples
Eligibility criteria and study design have been previously described.
This was an open-label, randomized, phase III trial comparing
erlotinib plus GEMOX with GEMOX alone as a first-line treatment
for advanced BTCs [11]. The primary endpoint was PFS and analyses
were conducted by intention to treat (ITT). The study included 268
randomized patients and a separate written consent for the optional
correlative study was obtained to allow participation in the
exploratory biomarker study of archival tumor specimens. Specimens
were labeled with site of origin and a unique patient identifier.
Sixty-four patients (48.1%) were available for mutational analysis in
the chemotherapy alone group (n = 131) and 61 (45.1%) in the
chemotherapy plus erlotinib group (n = 135).
DNA Extraction and Mutation Analysis for EGFR, KRAS,
and PIK3CA
DNAwas extracted from five 10-μm formalin-fixed paraffin-embedded
sections containing a representative portion of each tumor block, using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). A pathologist
(K.-T.J.) reviewed each slide and verified the presence of adequate tumor
tissue with greater than 50% representative malignant cells.
Peptide nucleic acid (PNA)–locked nucleic acid polymerase
chain reaction (PCR) clamp reactions were carried out using the
PNA-Clamp EGFR, PNA-Clamp KRAS, and PNA-Clamp PIK3CA
Mutation Detection kits (Panagene, Inc, Daejeon, Korea), as
described previously [20,21]. Briefly, this reaction consists of the
following: all reactions were done in 20-μl volumes using 10 to 25 ng
of template DNA, primer and PNA probe set, and SYBR Green PCR
master mix. All necessary reagents are included with the kit. Real-time
PCR reactions of PNA-mediated clamping PCR were performed
using a CFX 96 System (Bio-Rad, Foster City, California). PCR
cycling conditions were a 5-minute holding period at 94°C,
followed by 40 cycles of 94°C for 30 seconds, 70°C for 20 seconds,
63°C for 30 seconds, and 72°C for 30 seconds. Detection of each of
the 29 mutations in EGFR exons 18 to 21, 7 mutations in KRAS
exon 2, and 3 mutations in PIK3CA exons 2 and 9 was possible
using one-step PNA-mediated real-time PCR clamping.
Statistical Analysis
PFS, OS, and overall RR were evaluated with respect to tumor
mutation status (KRAS and PIK3CA). PFS and OS were analyzed by
the Kaplan-Meier method and stratified log-rank test. The predefined
variables used to investigate the association of potential prognostic
factors for PFS were age, sex, primary site, differentiation, disease
status, liver-only metastasis, number of involved sites, the use of
erlotinib, KRAS mutation status, PIK3CA mutation status, and any
mutation of EGFR, KRAS, or PIK3CA. The Cox proportional
hazards model was used for univariate and multivariate analyses to
assess the independent effects of variables and to obtain their Hazard
Ratio (HR estimates). P b .05 values were considered significant.
Figure 2. PFS. (A) Overall and (B) according to GEMOX with or without erlotinib.
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Patients and Samples
In our previous study that included 268 patients randomly
assigned to receive GEMOX plus erlotinib (N = 133) or GEMOX
alone (N = 135), 227 events were observed over a median follow-up
time of 15 months (range, 11.0-18.9 months) [11].
In the initial analysis, we were able to analyze either EGFR
overexpression or KRAS mutation status from 60 tissue specimens
(22.3% of the ITT population) that had sufficient DNA (Figure 1).
In contrast, a total of 125 tissue specimens (mutation analysis
population; 46.6% of the ITT population) was included for current
analysis (Figure 1).
The baseline characteristics were well balanced between the treatment
groups in the ITT and mutation analysis population (Table 1). In the
mutation analysis population (N = 125), 64 patients (51.2%) received
GEMOX alone and 61 (48.9%) received GEMOX plus erlotinib.
Frequency of EGFR, KRAS, and PIK3CA Mutations
The mutational status of EGFR, KRAS, and PIK3CA was
identifiable in 116, 121, and 118 patients, respectively. EGFR
mutations were found in 2 of 116 patients (1.7%). Two
cholangiocarcinoma patients harbored EGFR T790M mutations
and were treated with GEMOX alone. Following chemotherapy, one
of these patients showed a complete response, while the second
patient maintained stable disease. The incidence of KRAS mutations
was 9.9% [12 of 121, 4 GBCs, 7 cholangiocarcinomas, and 1
Ampulla of Vater (AoV) cancer]. Most KRAS mutations occurred at
codon 12 (11 of 12 patients, 91.6%). PIK3CA mutations, which
were observed in 12 of 118 patients (10.1%), occurred mainly in exons
9 (10 patients) and 10 (2 patients). All patients with PIK3CAmutations
had cholangiocarcinoma (Table 2). Mutations in both KRAS and
PIK3CA were found in the tumor tissues from three patients.
Impact ofMutation of KRAS and PIK3CA on Clinical Outcomes
The statistical significances (P value) for RR, PFS, and OS in the
ITT and mutational analysis populations were comparable (Table 3).Patients with wild-type KRAS tumors who received erlotinib plus
GEMOX (GEMOXT) had significantly increased overall RR
compared with those who received GEMOX alone (Table 3).
However, there was no significant difference in RR in patients with
KRAS mutations between the GEMOX with and without erlotinib
treatment groups. In patients whose tumors carried wild-type
PIK3CA, erlotinib plus GEMOX showed a favorable trend for
overall response, but no statistically significance difference (P = .08).
In 95 patients with both wild-type KRAS and PIK3CA, there was
evidence of a benefit associated with the addition of erlotinib to
GEMOX in relation to RR as compared with GEMOX alone (P =
.04). No significant difference was observed in PFS and OS between
the treatment groups, irrespective of KRAS or PIK3CA mutation
status. Additionally, in 92 patients with wild-type EGFR, KRAS, and
PIK3CA, the addition of erlotinib to GEMOX improved tumor
responses (P = .03; Table 3).
In the mutation analysis population (n = 125), the estimated
median PFS time was 4.8 months [95% confidence interval (CI),
3.2-6.4]. Median PFS was not significantly different in either
treatment group [2.7 months (95% CI, 1.3-4.1) in GEMOX alone
group and 6.2 months (95% CI, 4.5-7.8) in GEMOX plus erlotinib
group, P = .172; Figure 2]. There was also no significant difference in
PFS between the GEMOX with and without erlotinib groups in
either patients with wild-type EGFR/KRAS/PIK3CA or with any
mutation in EGFR or KRAS or PIK3CA (Figure 3). Univariate
analysis revealed that PFS was not associated with the addition of
erlotinib to chemotherapy, mutation status of KRAS and PIK3CA,
and wild-type status of EGFR/KRAS/PIK3CA (Table 4).
Discussion
Emerging evidence has implicated the EGFR pathway as a potential
therapeutic target in BTC [22,23]. Oncogenic activation of the
EGFR pathway, including EGFR-RAS-RAF or EGFR-PIK3CA
signaling, is a key mechanism in the efficacy of EGFR-directed
therapy [16]. Presently, we do not know the biologic significance of
mutations in these genes or to what extent they confer sensitivity to
Figure 3. PFS according to GEMOX with or without erlotinib in patients with (A) EGFR/KRAS/PIK3CA wild type and (B) any mutation of
EGFR or KRAS or PIK3CA.
44 Molecular Subgroup Analysis in Advanced BTC Kim et al. Translational Oncology Vol. 8, No. 1, 2015currently available small-molecule inhibitors, including erlotinib, in
BTCs. We have previously analyzed the efficacy of chemotherapy plus
erlotinib with respect to KRAS status using data from our previous
phase III trial for BTC. Clinical samples from which tumor DNATable 4. Prognostic Factors for PFS in Univariate Analysis
Characteristics Median PFS
(95% CI),
Months
Univariate
HR (95% CI) P
Age 0.880 (0.606-1.278) .502
≤60 5.93 (3.57-8.28)
N60 4.00 (1.62-6.37)
Sex 0.942 (0.775-1.144) .546
Male 4.17 (2.30-6.03)
Female 5.93 (3.90-7.95)
Primary sites 1.003 (0.666-1.510) .989
Cholangiocarcinoma 4.90 (3.13-6.66)
GBC/AoV cancer 3.63 (0.05-7.20)
Differentiation 1.114 (0.763-1.626) .578
Well/moderate 4.57 (1.61-7.52)
Poorly 4.90 (2.43-7.36)
Disease status 1.406 (0.928-2.130) .108
Recurrent 6.60 (3.77-9.42)
Primarily metastatic 4.17 (1.93-6.40)
Liver-only metastasis 1.239 (0.761-2.018) .388
Yes 3.87 (1.72-6.01)
No 4.90 (3.09-6.70)
Number of metastatic sites 0.969 (0.600-1.562) .896
1 4.30 (2.38-6.21)
2 ≤ 6.00 (3.45-8.54)
GEMOX 0.772 (0.532-1.122) .175
Without erlotinib 2.77 (1.34-4.19)
With erlotinib 6.20 (4.52-7.87)
KRAS 0.846 (0.427-1.626) .631
Wild type 4.90 (3.04-6.76)
Mutant type 3.17 (0.00-7.31)
PIK3CA 0.974 (0.519-1.828) .934
Wild type 5.10 (3.25-6.95)
Mutant type 3.00 (0.00-6.46)
Mutation status 1.095 (0.662-1.812) .723
EGFR/KRAS/PIK3CA wild 5.10 (3.19-7.00)
Any mutation 3.17 (0.36-5.97)could be successfully analyzed were initially available for a subset of
22.3% of the ITT population. Subsequently, through the use of
improved ascertainment, the total number of patients from whom
tumor KRAS mutation status could be assessed was approximately
doubled to 46.6% of the ITT population (mutation analysis
population). Moreover, mutation status for EGFR and PIK3CA was
analyzed in this mutation analysis population. Herein, we report the
impact of the mutation status of EGFR, KRAS, and PIK3CA on the
clinical outcomes of patients treated with a small-molecule inhibitor
of the EGFR kinase domain in an expanded patient cohort.
This analysis suggested that KRAS mutation might be a predictor
of resistance to the small-molecule inhibitor erlotinib in BTCs. It is
yet unknown if KRASmutation in BTCs is a negative predictor of the
effectiveness of anti-EGFR treatment. In colorectal cancer, it has been
established that KRAS mutation precludes any therapeutic benefit
from anti-EGFR antibodies (cetuximab and panitumumab) [24,25].
In addition, we have also published that KRAS mutations might be
negative predictive biomarkers in advanced pancreatic cancer patients
who have been treated with a gemcitabine-erlotinib combination
[26]. In contrast, this concept has not yet been confirmed in other
types of cancer including BTCs. Gruenberger et al. investigated the
efficacy of gemcitabine, oxaliplatin, and cetuximab combinations in
patients with advanced BTCs and reported that two of three patients
harboring KRAS mutations showed a partial response to cetuximab
plus chemotherapy [27]. We also analyzed KRAS mutations in the 60
specimens in our study and showed that three of six patients with
KRAS mutations responded to erlotinib [11]. These findings suggest
that anti-EGFR therapies might be beneficial, irrespective of KRAS
mutational status, in BTCs. However, our sample size was too small
to allow us to draw any significant conclusions. There is a discrepancy
between our current findings and previous reports, which may have
resulted from our small sample size, geographic differences, different
testing techniques, and heterogeneity of the patient populations
between studies [11,27]. Although our present analysis used a larger
sample set as compared with previous analyses, the sample size of this
study was still too small.
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with a lack of erlotinib activity in BTCs that retain wild-type KRAS.
PIK3CA mutations, which are commonly found in colon, breast,
gastric, and brain cancers, are rarely found in BTC [15]. PIK3CA
mutations mainly occur in exons 9 (E542K, E545K) and 20 (H1047R)
[18,28,29]. In our analysis, 12 patients had PIK3CA mutations, with
10 having a mutation in exon 9 and 2 in exon 20. Of the 12 patients
with PIK3CAmutation, 3 patients also had aKRASmutation. In the 95
patients with both wild-type KRAS and PIK3CA, there was evidence of
a benefit associated with the addition of erlotinib to GEMOX, as
compared with GEMOX alone, with respect to RR (P = .04). However,
in 9 patients with wild-type KRAS and PIK3CAmutations (8 in exon 9
and 1 in exon 20), the addition of erlotinib to chemotherapy did not
result in an improved response (P = .08). The effect of the mutation
status of PIK3CA on anti-EGFR therapies has been studied in KRAS
wild-type colorectal cancers [13,18,30,31]. To the best of our
knowledge, this is the first report to evaluate the correlation between
the mutation status of PIK3CA and the activity of the anti-EGFR
therapy erlotinib in BTCs. Clearly, however, the role of KRAS and
PIK3CA mutations in response to treatment with anti-EGFR agents
needs further analysis in a larger homogeneous population.
EGFR mutations occur in a significant minority of patients (13-
15%) with BTC; however, the results of mutation analyses from two
studies were quite different [13,14]. In our study, EGFR mutation was
found in 2 of 116 patients (1.7%). These two patients harbored an
EGFR T790Mmutation that is known to confer resistance to currently
available small-molecule inhibitors. This EGFR T790M mutation was
not described in previous studies [13,14].
Our analysis revealed that KRAS mutational status might be
considered a negative predictive biomarker for response to erlotinib in
BTCs. Additionally, the mutation status of PIK3CA may be a
determinant in the decision as to whether to add erlotinib to
chemotherapy in KRAS wild-type BTCs. However, tissue availability
was a potential limitation of the current retrospective mutational
analysis. This is as critical an issue in BTC research as it is in
pancreatic cancer. In the current study, about 20% of patients in the
ITT population underwent prior surgery, as did about 30% of
patients in the mutation analysis population, thereby effectively
limiting the availability and adequacy of surgical specimens for
biomarker analysis. Therefore, possible selection bias in the current
study may make definitive conclusions difficult and may have
influenced the prognostic and predictive results of KRAS and
PIK3CA status, which need to be interpreted with caution and
validated. Further prospective studies are needed for defining
predictive or prognostic biomarkers. The rarity of BTC hinders
clinicians from conducting definitive trials and from producing
rigorous scientific data. Thus, coordination of trials among
institutions and cooperative groups, both nationally and internation-
ally, will be the key to improving treatment outcomes in BTCs.
Additionally, because of the heterogeneity of BTCs, appropriate
stratification using clinical or molecular factors will help to define
more clearly outcomes of the research.
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